Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Wall St rises at open as investors cheer rate cut prospects
- Stocks will be hostage to earnings delivery in 2024 rather than yields - JPMorgan
- General Motors (GM) surges on $10 billion buyback plan, increased dividend
- Bill Ackman sees risk of hard landing if Fed doesn't start cutting soon
- Bonds bask in talk of Fed interest rate cuts
MINNEAPOLIS, May 22, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that, effective May 19, 2023, the Company’s independent directors approved equity awards under Nuwellis’ 2021 Inducement Plan, as material inducements to five individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder-approved equity plan.
In connection with entering into employment with Nuwellis, Inc., the individuals, who were not previously employees or directors of Nuwellis, received options to purchase an aggregate of 1,103 shares of the Company’s common stock. 720 of the options have an exercise price of $3.02 per share, the closing price of Nuwellis’ common stock on May 19, 2023, the effective date of those grants. 383 of the options have an exercise price of $2.87 per share, the closing price of Nuwellis’ common stock on May 22, 2023, the effective date of that grant. The options have a ten-year term and vest over a period of four years, with 25% vesting one year after the date of grant and the remaining 75% vesting in 36 approximately equal monthly increments, provided the new hire’s employment is continuing on each such date, subject to acceleration or forfeiture upon the occurrence of certain events as set forth in the new hire’s option agreement.
About NuwellisNuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information, visit www.nuwellis.com or visit us on LinkedIn and Twitter.
About the Aquadex SmartFlow SystemThe Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Investors: Vivian CervantesGilmartin Group [email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nuwellis (NUWE) Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
- Rule4 Ranked #1 on Outside's 2023 Best Places to Work
- COVID-19’s impact on the vagus nerve, inflammatory reflex & long COVID: Feinstein Institutes & Karolinska Institutet study outlines potential therapies
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!